|Full-Year 2018 Financial Results reporting*||February 7, 2019|
|First Quarter 2019 Financial Results reporting*||April 18, 2019|
|Annual General Meeting 2019||May 3, 2019|
|Half-Year 2019 Financial Results reporting*||July 23, 2019|
*We will be in a silent period for 10 days ahead of the financial reporting.
Phase 3 initiation: Aprocitentan for resistant hypertension management
Phase 3 Advancing: Clazosentan for cerebral vasospasm
In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.
Phase 3 initiation: ACT-541468 for insomnia
Phase 3 initiation: Lucerastat for Fabry disease
In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.
Share this page:
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.